市场见解

Neuren Pharmaceuticals (ASX:NEU) share price rockets 100% on study results

Why are investors so excited about Neuren Pharmaceuticals today?
The post Neuren Pharmaceuticals (ASX:NEU) share price rockets 100% on study results appeared first on The Motley Fool Australia. –

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is soaring to yearly highs on the back of positive phase three clinical trial results.

Shares are currently swapping hands at $3.40 apiece, up exactly 100% from yesterday’s close.

Let’s investigate what triggered the major boost for the drug therapy company today.

Why did Neuren announce?

Neuren reported positive results from phase three trials into the use of trofinetide to treat young women with Rett syndrome. Trofinetide has been granted fast-track status and orphan drug designation for Rett syndrome.

Acadia Pharmaceuticals (NASDAQ: ACAD) is conducting and funding the trials, but Neuren is eligible to receive milestone payments of up to US$455 million (AU$645 million). Neuren is also eligible for royalties on trofinetide sales if the drug is approved by the FDA.

Acadia is planning to meet with the FDA for a new drug application in the middle of 2022.

Neuren predicts it would earn AU$111 million in revenue over 2022 and 2023 for Rett syndrome, plus double-digit percentage royalties on net sales if trofinetide is approved and launched in the US.

Rett syndrome is a rare genetic mutation affecting brain development, primarily in girls.

What did management say?

Commenting on the news driving the Neuren Pharmaceuticals share price today, CEO Jon Pilcher said:

We are delighted with these robustly positive results and are now eager to see trofinetide progress through the regulatory approval process.

We are very grateful to the Rett syndrome community — the patients, their caregivers, study site personnel, physicians and everyone who participated in the Lavender study, as well as in Neuren’s two Phase 2 studies that paved the way.

Neuren Pharmaceuticals share price snapshot

The Neuren Pharmaceuticals share price has skyrocketed 164% this year to date. It has also gained 170% over the past 12 months.

Earlier today, the share price reached $3.56, a yearly high. The yearly low is $1.18.

The post Neuren Pharmaceuticals (ASX:NEU) share price rockets 100% on study results appeared first on The Motley Fool Australia.

Should you invest $1,000 in Neuren Pharmaceuticals right now?

Before you consider Neuren Pharmaceuticals, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Neuren Pharmaceuticals wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why the Bank of Queensland (ASX:BOQ) share price is racing 5% higher today

Betashares CRYPTO ETF (ASX:CRYP) drops 16% in the past week. What’s next?

Why this top broker says the Cochlear (ASX:COH) share price is heading lower

Emerald Resources (ASX:EMR) share price lifts on $117 million acquisition

Why did the Woodside (ASX:WPL) share price go backward in November?

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!